{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:26:10Z","timestamp":1793939170995,"version":"4.8.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cord blood (CB) transplantation is hampered by low cell dose and high nonrelapse mortality (NRM). A phase 1-2 trial of UM171-expanded CB transplants demonstrated safety and favorable preliminary efficacy. The aim of the current analysis was to retrospectively compare results of the phase 1-2 trial with those after unmanipulated CB and matched-unrelated donor (MUD) transplants. Data from recipients of CB and MUD transplants were obtained from the Center for International Blood and Marrow Transplant Research (CIBMTR) database. Patients were directly matched for the number of previous allogeneic hematopoietic stem cell transplants (alloHCT), disease and refined Disease Risk Index. Patients were further matched by propensity score for age, comorbidity index, and performance status. Primary end points included NRM, progression-free survival (PFS), overall survival (OS), and graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) at 1 and 2 years after alloHCT. Overall, 137 patients from CIBMTR (67 CB, 70 MUD) and 22 with UM171-expanded CB were included. NRM at 1 and 2 years was lower, PFS and GRFS at 2 years and OS at 1 year were improved for UM171-expanded CBs compared with CB controls. Compared with MUD controls, UM171 recipients had lower 1- and 2-year NRM, higher 2-year PFS, and higher 1- and 2-year GRFS. Furthermore, UM171-expanded CB recipients experienced less grades 3-4 acute GVHD and chronic GVHD compared with MUD graft recipients. Compared with real-world evidence with CB and MUD alloHCT, this study suggests that UM171-expanded CB recipients may benefit from lower NRM and higher GRFS. This trial was registered at www.clinicaltrials.gov as #NCT02668315.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010599","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T15:51:54Z","timestamp":1689781914000},"page":"5717-5726","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["Improved outcomes of UM171\u2013expanded cord blood transplantation compared with other graft sources: real-world evidence"],"prefix":"10.1182","volume":"7","author":[{"given":"Sandra","family":"Cohen","sequence":"first","affiliation":[{"name":"1Institut Universitaire d'H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est de l\u2019\u00cele de Montr\u00e9al, Montr\u00e9al, QC, Canada"},{"name":"2Department of Medicine, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Bambace","sequence":"additional","affiliation":[{"name":"1Institut Universitaire d'H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est de l\u2019\u00cele de Montr\u00e9al, Montr\u00e9al, QC, Canada"},{"name":"2Department of Medicine, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1899-0164","authenticated-orcid":false,"given":"Imran","family":"Ahmad","sequence":"additional","affiliation":[{"name":"1Institut Universitaire d'H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est de l\u2019\u00cele de Montr\u00e9al, Montr\u00e9al, QC, Canada"},{"name":"2Department of Medicine, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Roy","sequence":"additional","affiliation":[{"name":"1Institut Universitaire d'H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est de l\u2019\u00cele de Montr\u00e9al, Montr\u00e9al, QC, Canada"},{"name":"2Department of Medicine, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Tang","sequence":"additional","affiliation":[{"name":"3Center for International Blood and Marrow Transplant Research, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"3Center for International Blood and Marrow Transplant Research, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Burns","sequence":"additional","affiliation":[{"name":"3Center for International Blood and Marrow Transplant Research, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Barab\u00e9","sequence":"additional","affiliation":[{"name":"4Centre Hospitalier Universitaire de Qu\u00e9bec, Universit\u00e9 Laval, Qu\u00e9bec, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Bernard","sequence":"additional","affiliation":[{"name":"1Institut Universitaire d'H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est de l\u2019\u00cele de Montr\u00e9al, Montr\u00e9al, QC, Canada"},{"name":"2Department of Medicine, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1460-7287","authenticated-orcid":false,"given":"Jean-S\u00e9bastien","family":"Delisle","sequence":"additional","affiliation":[{"name":"1Institut Universitaire d'H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est de l\u2019\u00cele de Montr\u00e9al, Montr\u00e9al, QC, Canada"},{"name":"2Department of Medicine, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kiss","sequence":"additional","affiliation":[{"name":"1Institut Universitaire d'H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est de l\u2019\u00cele de Montr\u00e9al, Montr\u00e9al, QC, Canada"},{"name":"2Department of Medicine, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvy","family":"Lachance","sequence":"additional","affiliation":[{"name":"1Institut Universitaire d'H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est de l\u2019\u00cele de Montr\u00e9al, Montr\u00e9al, QC, Canada"},{"name":"2Department of Medicine, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis-Claude","family":"Roy","sequence":"additional","affiliation":[{"name":"1Institut Universitaire d'H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est de l\u2019\u00cele de Montr\u00e9al, Montr\u00e9al, QC, Canada"},{"name":"2Department of Medicine, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Veilleux","sequence":"additional","affiliation":[{"name":"1Institut Universitaire d'H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est de l\u2019\u00cele de Montr\u00e9al, Montr\u00e9al, QC, Canada"},{"name":"2Department of Medicine, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Sauvageau","sequence":"additional","affiliation":[{"name":"1Institut Universitaire d'H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est de l\u2019\u00cele de Montr\u00e9al, Montr\u00e9al, QC, Canada"},{"name":"2Department of Medicine, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"},{"name":"5Institut de Recherche en Immunologie et Canc\u00e9rologie, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"10","key":"2023101013213211400_bib1","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/bmt.2010.5","article-title":"Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation","volume":"45","author":"Pallua","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"2023101013213211400_bib2","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 2","key":"2023101013213211400_bib3","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1002\/sctm.20-0495","article-title":"Umbilical cord blood transplantation: still growing and improving","volume":"10","author":"Zhu","year":"2021","journal-title":"Stem Cells Transl Med"},{"issue":"4","key":"2023101013213211400_bib4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood-2013-02-453175","article-title":"Umbilical cord blood transplantation: the first 25 years and beyond","volume":"122","author":"Ballen","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2023101013213211400_bib5","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2023101013213211400_bib6","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1182\/bloodadvances.2022009253","article-title":"T-replete cord transplants give superior outcomes in high risk and relapsed\/refractory paediatric myeloid malignancy","volume":"7","author":"Horgan","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2023101013213211400_bib7","doi-asserted-by":"crossref","first-page":"495.e1","DOI":"10.1016\/j.jtct.2021.02.022","article-title":"Favorable outcomes after single cord blood transplantation for patients with high-risk hematologic diseases: a single-institute retrospective analysis","volume":"27","author":"Wada","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"2023101013213211400_bib8","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/bloodadvances.2018029157","article-title":"CD34+ cell content of 126 341 cord blood units in the US inventory: implications for transplantation and banking","volume":"3","author":"Barker","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2023101013213211400_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2013-05-506253","article-title":"Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy","volume":"123","author":"Eapen","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2023101013213211400_bib10","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.bbmt.2020.07.030","article-title":"Guidelines for cord blood unit selection","volume":"26","author":"Politikos","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"2023101013213211400_bib11","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/blood-2010-05-285304","article-title":"Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood","volume":"116","author":"Brunstein","year":"2010","journal-title":"Blood"},{"key":"2023101013213211400_bib12","doi-asserted-by":"crossref","first-page":"610514","DOI":"10.4061\/2011\/610514","article-title":"Risk factors and options to improve engraftment in unrelated cord blood transplantation","volume":"2011","author":"Petropoulou","year":"2011","journal-title":"Stem Cells Int"},{"issue":"6203","key":"2023101013213211400_bib13","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1126\/science.1256337","article-title":"Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal","volume":"345","author":"Fares","year":"2014","journal-title":"Science"},{"issue":"1","key":"2023101013213211400_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.stem.2020.12.002","article-title":"UM171 preserves epigenetic marks that are reduced in ex\u00a0vivo culture of human HSCs via potentiation of the CLR3-KBTBD4 complex","volume":"28","author":"Chagraoui","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"2","key":"2023101013213211400_bib15","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1016\/S2352-3026(19)30202-9","article-title":"Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study","volume":"7","author":"Cohen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"23","key":"2023101013213211400_bib16","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2023101013213211400_bib17","doi-asserted-by":"crossref","first-page":"409.e1","DOI":"10.1016\/j.jtct.2022.04.012","article-title":"Updated trends in hematopoietic cell transplantation in the United States with an additional focus on adolescent and young adult transplantation activity and outcomes","volume":"28","author":"Phelan","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2023101013213211400_bib18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2023101013213211400_bib19","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2023101013213211400_bib20","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2023101013213211400_bib21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2023101013213211400_bib22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jtct.2021.01.024","article-title":"Guidelines for infection prophylaxis, monitoring and therapy in cord blood transplantation","volume":"27","author":"Olson","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"2023101013213211400_bib23","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jtct.2021.03.012","article-title":"Guidelines for the prevention and management of graft-versus-host disease after cord blood transplantation","volume":"27","author":"Ponce","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2023101013213211400_bib24","doi-asserted-by":"crossref","first-page":"76.e1","DOI":"10.1016\/j.bbmt.2020.09.031","article-title":"UM171-expanded cord blood transplants support robust T cell reconstitution with low rates of severe infections","volume":"27","author":"Dumont-Lagac\u00e9","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"2023101013213211400_bib25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1200\/JCO.18.00053","article-title":"Phase I\/II study of stem-cell transplantation using a single cord blood unit expanded ex\u00a0vivo with nicotinamide","volume":"37","author":"Horwitz","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2023101013213211400_bib26","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/blood.2021011719","article-title":"Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study","volume":"138","author":"Horwitz","year":"2021","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/19\/5717\/2083784\/blooda_adv-2023-010599-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/19\/5717\/2083784\/blooda_adv-2023-010599-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T13:21:56Z","timestamp":1696944116000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/19\/5717\/496897\/Improved-outcomes-of-UM171-expanded-cord-blood"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":26,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023,10,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010599","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}